Detalles de la búsqueda
1.
Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis.
Hepatol Res;
53(4): 301-311, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36507871
2.
Improved Liver Function After Sustained Virologic Response Enhanced Prognosis in Hepatitis C with Compensated Advanced Liver Fibrosis.
Dig Dis Sci;
68(5): 2115-2122, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36526814
3.
Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.
Hepatology;
74(5): 2452-2466, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34105780
4.
Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy.
Hepatol Res;
52(3): 298-307, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34918428
5.
Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma.
Hepatol Res;
52(7): 630-640, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35417606
6.
Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis.
Hepatol Res;
52(10): 824-832, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35749289
7.
Prognostic impact of worsening of esophageal varices after balloon-occluded retrograde transvenous obliteration.
J Gastroenterol Hepatol;
37(6): 1148-1155, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35430734
8.
Prediction Model for Intrahepatic Distant Recurrence After Radiofrequency Ablation for Primary Hepatocellular Carcinoma 2 cm or Smaller.
Dig Dis Sci;
67(12): 5704-5711, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35353331
9.
Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment.
Hepatol Res;
51(5): 517-527, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33507588
10.
Lower Serum Sodium Levels Are Associated with the Therapeutic Effect of Sorafenib on Hepatocellular Carcinoma.
Dig Dis Sci;
66(5): 1720-1729, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32556820
11.
Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma.
Hepatol Res;
50(3): 365-373, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31661722
12.
Clinical outcomes of direct-acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment.
Hepatol Res;
50(10): 1118-1127, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32678925
13.
Initial treatment response to transarterial chemoembolization as a predictive factor for Child-Pugh class deterioration prior to refractoriness in hepatocellular carcinoma.
Hepatol Res;
50(11): 1275-1283, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32812315
14.
Hepatocellular carcinoma occurrence does not differ between interferon-based and interferon-free treatment with liver histological assessment.
Hepatol Res;
50(3): 313-320, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31747479
15.
Therapeutic efficacy of lenvatinib in hepatocellular carcinoma patients with portal hypertension.
Hepatol Res;
50(9): 1091-1100, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32559342
16.
Predictive factors of anemia during sofosbuvir and ribavirin therapy for genotype 2 chronic hepatitis C patients.
Hepatol Res;
49(8): 853-859, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31009550
17.
Cotreatment with lenvatinib and warfarin potassium caused prothrombin time prolongation.
Hepatol Res;
49(11): 1357-1361, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31119866
18.
Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response.
Hepatol Res;
49(5): 570-578, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30623521
19.
Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: Analysis of a Japanese prospective cohort.
Hepatol Res;
47(13): 1438-1444, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28585404
20.
Ultra-deep sequencing analysis of resistance-associated variants during retreatment with simeprevir-based triple therapy after failure of telaprevir-based triple therapy in patients with genotype 1 hepatitis C virus infection.
Hepatol Res;
47(8): 773-782, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27593967